Is it Possible to have Cheaper Drugs and Preserve the Incentive to Innovate? The Benefits of Privatizing the Drug Approval Process

Robert Sauer, Corinne Sauer

Research output: Contribution to journalArticlepeer-review

98 Downloads (Pure)

Abstract

In this paper, we argue that lower prices for pharmaceuticals can be achieved by fostering a new type of competition in the pharmaceutical industry. Lower drug development costs, and hence prices, can be brought about by abolishing national drug administrations and replacing them with private certification boards that compete on the basis of safety, efficiency and cost of their drug approval process. A major benefit of this type of privatization is that it would not necessitate limits on data exclusivity in order to achieve lower prices. Drug approval privatization could achieve the same positive results as generic competition, in terms of lower costs and prices, without the negative effects of intellectual property rights violation and the consequent discouragement of innovative activities.
Original languageEnglish
Pages (from-to)509-524
Number of pages16
JournalJournal of Technology Transfer
Volume32
Issue number5
Publication statusPublished - Oct 2007

Keywords

  • pharmaceuticals
  • Drug approval
  • Privatization
  • Data exclusivity
  • Innovation

Cite this